lifestyle.capitolhilltimes.com

Author: CASI Pharmaceuticals

CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel

February 25, 2026
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

January 15, 2026
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

January 12, 2026
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

December 23, 2025
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

December 12, 2025
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

December 8, 2025